AstraZeneca Exanta Liver Safety Is Key Approval Issue, Company Says
Executive Summary
AstraZeneca's discussions with FDA over the safety profile of its investigational anticoagulant Exanta will center on elevated liver enzyme levels reported during clinical trials
You may also be interested in...
Astra Joint Venture Keeps Paying Dividends For Merck; “True Up” Due In 2008
AstraZeneca is still estimating that its final payment in the break-up of the Merck joint venture will be $4.7 bil. in 2008
AstraZeneca Crestor, Exanta Promotions Will Focus On Dosing Advantages
One of AstraZeneca's promotional messages for its statin Crestor (rosuvastatin) will likely focus on the ability of the 10 mg dose to achieve target cholesterol levels without the need for up-titration
AstraZeneca Exanta NDA Filing Set For 2003; Cost-Effective Vs. Warfarin?
AstraZeneca intends to position its anticoagulant Exanta (ximelagatran) as a cost-effective alternative to warfarin in the antithrombotic market